Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neuroprotective therapy

S L Hickenbottom1, J Grotta

  • 1Department of Neurology, University of Texas at Houston Medical School, 77030, USA.

Seminars in Neurology
|February 5, 1999
PubMed
Summary
This summary is machine-generated.

Neuroprotection aims to prevent delayed brain cell death after stroke by targeting the ischemic cascade. While many agents show promise in animal models, human trials yield mixed results, necessitating further research for effective stroke treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of adult moyamoya disease by encephalo-duro-arterio-synangiosis: Five case reports.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2015
Same author

Does the cognitive measure Cog-4 show improvement among patients treated with thrombolysis after acute stroke?

International journal of stroke : official journal of the International Stroke Society·2012
Same author

IV tissue plasminogen activator use in acute stroke: experience from a statewide registry.

Neurology·2006
Same author

A national study of the quantity and cost of informal caregiving for the elderly with stroke.

Neurology·2002
Same author

Acute stroke care in non-urban emergency departments.

Neurology·2001
Same author

Combination Therapy Stroke Trial: recombinant tissue-type plasminogen activator with/without lubeluzole.

Cerebrovascular diseases (Basel, Switzerland)·2001
Same journal

Isolated Cranial Tremors: A Reappraisal.

Seminars in neurology·2026
Same journal

Dystonia and Tremor.

Seminars in neurology·2026
Same journal

Pendular nystagmus and oculopalatal tremor.

Seminars in neurology·2026
Same journal

Sanjay Pandey, MBBS, MD, DNB, DM, FIAN, and Aasef Shaikh, MD, PhD.

Seminars in neurology·2026
Same journal

Tremor.

Seminars in neurology·2026
Same journal

Carotid Disease.

Seminars in neurology·2026
See all related articles

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Delayed neuronal injury after ischemia, known as the "ischemic cascade," presents therapeutic targets.
  • Preclinical studies in animal models demonstrate neuroprotective potential of various agents against cerebral ischemia.

Purpose of the Study:

  • To review the therapeutic strategies targeting the ischemic cascade for neuroprotection.
  • To evaluate the efficacy of neuroprotective agents in human clinical trials.

Main Methods:

  • Review of preclinical studies in animal models of global and focal cerebral ischemia.
  • Analysis of human clinical trial data for ten classes of neuroprotective agents that reached Phase III efficacy trials.

Main Results:

  • Numerous agents showed neuroprotection in animal models targeting different steps of the ischemic cascade.

Related Experiment Videos

  • Ten classes of neuroprotective agents (e.g., calcium channel antagonists, NMDA receptor antagonists, tirilizad, ICAM-1 antibody) have reached Phase III trials with mixed results.

    • Conclusions:

    • Current neuroprotective agents have shown limited success in human trials for acute ischemic stroke.
    • Future stroke treatment may involve combination therapies targeting multiple sites within the ischemic cascade.